Usage of infliximab biosimilars in select countries 2018

Uptake of infliximab biosimilars in select countries as of 2018, by share of units

Last update:

Oct 9, 2024

Author:

��ƽ�� Research Department

Region:

OECD

Survey time period:

From 01/01/2018 to 31/12/2018

In Norway, the uptake of infliximab biosimilars as of 4th quarter 2018 was 98 percent, and thus the highest among developed countries (OECD). That means that 98 percent of all used units of that drug were biosimilars.

We’re happy to help

Get in touch with us for additional information

Feel free to contact us anytime. We will respond to your inquiry as quickly as possible.

Get in touch

�����ƽ��

Uptake of infliximab biosimilars in select countries as of 2018, by share of units

Get in touch with us for additional information

��ƽ��